# Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

> **NCT01799538** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 100 (estimated)

## Conditions studied

- Lymphangioleiomyomatosis

## Interventions

- **DRUG:** albuterol inhaler
- **DRUG:** albuterol nebulizer
- **PROCEDURE:** PFT

## Key facts

- **NCT ID:** NCT01799538
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2013-06-10
- **Primary completion:** 2027-11-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01799538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01799538, "Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01799538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*